New research suggests that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who stop conventional diet and exercise plans.
Research printed in a prominent health publication points out that while obese people often shed a large proportion of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications should be cognizant of the risk of fast weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment weight in about one and a half years.
Weighing Therapies
The analysis, which reviewed 37 of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers point out that people who lose weight through lifestyle changes alone typically have a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Fast Regain
Experts believe the way of the injections is key to understanding the accelerated weight return.
These medications imitate a natural hormone called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating a significant risk."
A Chronic Issue?
The NHS recommend the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, considering the high risk of weight regain, the treatment should be considered long-term.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," comparing it to managing conditions like hypertension.
Patient Accounts
Individuals who have discontinued the jabs explain a intense resurgence of appetite.
"I experienced a trigger that goes on and you become starving," described one woman.
This challenge is worsened if users have not adopted permanent lifestyle or habit modifications during therapy.
Significant Use
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the past year, with desire remaining high.
- Use is higher among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, researchers emphasize that while the jabs are effective agents for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle changes.
